To test the hypothesis that miR-183-5p is involved in AGGF1-mediated treatment of hypertrophy and heart failure after TAC, we assessed the effect of AGGF1 protein treatment with or without an Antago-miR-183-5p inhibitor in mice after TAC. Here, AGGF1 is linked to persistent truncus arteriosus.